31 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
will be featured in a Science and Innovation Theater led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
Funds plc—Janus Henderson Global Life Fund (“Janus Capital”), and (iii) 655,927 shares of common stock held by Janus Henderson Biotech Innovation
8-K
EX-10.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
Shares: 228,572
[Signature Page to Securities Purchase Agreement]
PURCHASER:
JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED,
By: Janus … are to be registered:
JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED
Shares: 185,714
[Signature Page to Securities Purchase Agreement]
PURCHASER
8-K
EX-10.2
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
by their respective authorized signatories as of the date first indicated above.
PURCHASER:
JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED,
By: Janus … Henderson Global Life Sciences Fund
Janus Henderson Capital Funds PLC - Janus Henderson Global Life Sciences Fund
Janus Henderson Biotech Innovation Master
8-K
EX-99.1
9nqd8 0h0t9
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
ufa 0jm7oup
12 Nov 19
Crinetics Pharmaceuticals Reports Third Quarter 2019
4:01pm